Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20897913 | 1.00 | MAPT (0.39) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| SCHEMBL2522354 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| SCHEMBL1766017 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL10336280 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| Methane SCHEMBL11844540 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| SCHEMBL1766030 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| SCHEMBL1906087 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| SCHEMBL9498815 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| SCHEMBL1765933 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 | |
| SCHEMBL1766024 | 0.98 | MAPT (0.38) | MAPTCACNA1BAPBA1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1012 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026273-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| CN-116515492-A | Porous nano silicon dioxide loaded alkyl dithiocarbamate soil heavy metal passivator and preparation method and application thereof | 河南大学 | 2023-08-01 | — | — | CN | claimed |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | claimed |
| CN-116390731-A | Combined cancer therapy with pentaaza macrocyclic complexes and hormonal therapeutic agents | 加莱拉实验室有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| CN-116178808-A | Rubber outsole prepared by low-temperature vulcanization process and preparation method thereof | 江苏锐巴新材料科技有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-18 | — | — | US | claimed |
| EP-4157242-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Galera Labs, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | claimed |
| WO-2023009500-A1 | PENTAAZA MACROCYCLIC RING COMPLEX FOR ENHANCED SURGICAL TREATMENT | GALERA LABS, LLC (US) | 2023-02-02 | — | — | WO | claimed |
| EP-0309903-A1 | Epoxide and rubber based curable compositions having good adhesion direct to metal | PPG INDUSTRIES, INC. (US) | 1989-04-05 | — | — | EP | claimed |
| EP-0111326-B1 | PROCESS FOR THE MANUFACTURE OF CHIRAL AZETIDINONES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-01-11 | — | — | EP | claimed |
| EP-0266552-A1 | Process for production of isothiocyanates | STAUFFER CHEMICAL COMPANY (US) | 1988-05-11 | — | — | EP | claimed |
| US-4713467-A | OXIDATION OF DITHIOCARBAMATES; METAL CATALYST; H CONTROL | STAUFFER CHEMICAL COMPANY (US) | 1987-12-15 | — | — | US | claimed |
| US-4556434-A | Sewer cleaning foam composition and method | AIRRIGATION ENGINEERING COMPANY, INC. (US) | 1985-12-03 | — | — | US | claimed |
| US-4502972-A | ETHYLENE-PROPYLENE-DIENE TERPOLYMER | ETHYL CORPORATION (US) | 1985-03-05 | — | — | US | claimed |
| EP-0111326-A1 | Process for the manufacture of chiral azetidinones | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-06-20 | — | — | EP | claimed |
| US-4207196-A | OXIDATION RESISTANCE, DIALKYL DITHIOCARBAMATE SALTS AND TETRAALKYL THIURAM SULFIDES FOR POLYOLEFINS | THE B. F. GOODRICH COMPANY (US) | 1980-06-10 | — | — | US | claimed |
| US-4108858-A | Polyolefin quaternary pyridinium salts | ETHYL CORPORATION (US) | 1978-08-22 | — | — | US | claimed |
| US-4018611-A | Non-yellowing antimicrobial compositions comprising diiodomethyl sulfones | METALORGANA ETABLISSEMENT (FL) | 1977-04-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | MC2R, GHRHR, GNRHR | MAPT 4518/4885CACNA1B 4678/4885APBA1 2067/4885 |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | HDAC1, HDAC8, SIRT3 | MAPT 4618/4885CACNA1B 3899/4885APBA1 2567/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | MAPT 4687/4885CACNA1B 4523/4885APBA1 4281/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | MAPT 4687/4885CACNA1B 4523/4885APBA1 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.